Abstract
This study investigates potential links between cardiovascular disease and the use of traditional disease-modifying anti-rheumatic medications (DMARDs) in RA patients. 246 individuals with RA (82 with CVD and 164 without CVD) were investigated using a case-control strategy. Methotrexate (MTX) and sulfasalazine were used to classify the dataset (SSZ). "MTX alone", OR 0.18 (95% CI 0.09-0.74); "MTX with SSZ ever", OR 0.22 (95% CI 0.12-0.53). After further rectification, the treatment's risk reductions for the existence of rheumatoid factor remained considerable. Only the "MTX or SSZ" group had a substantial decrease in CVD risk after controlling for diabetes, hypertension, and high blood cholesterol levels. Rheumatoid factor substantially elevated the risk of cardiovascular disease, with odds ratios of 2.47 (95% confidence interval: 1.21 to 5.80). MTX and SSZ, the latter to a lesser degree, were related with a considerably lower risk of cardiovascular disease (CVD) compared to individuals with RA who had never taken either medication or combination. This research indicates that the use of DMARDs, namely MTX, resulted in a strong decrease of joint inflammation. It may help prevent the development of atherosclerosis and other cardiovascular diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
